CSS
ALNY icon

Cubist Systematic Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cubist Systematic Strategies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$1.82M Buy
4,000
+3,200
+400% +$1.3M 0.01% 1623
2025
Q2 		$261K Sell
800
-600
-43% -$166K ﹤0.01% 2502
2025
Q1 		$378K Buy
1,400
+100
+8% +$25.7K ﹤0.01% 2286
2024
Q4 		$306K Hold
1,300
– – ﹤0.01% 2397
2024
Q3 		$358K Sell
1,300
-49,800
-97% -$13M ﹤0.01% 2348
2024
Q2 		$12.4M Buy
51,100
+30,000
+142% +$4.74M 0.08% 315
2024
Q1 		$3.15M Buy
21,100
+4,400
+26% +$734K 0.02% 1293
2023
Q4 		$3.2M Buy
16,700
+1,000
+6% +$170K 0.02% 1156
2023
Q3 		$2.78M Sell
15,700
-900
-5% -$172K 0.02% 1131
2023
Q2 		$3.15M Hold
16,600
– – 0.02% 1139
2023
Q1 		$3.33M Buy
16,600
+2,600
+19% +$547K 0.02% 1260
2022
Q4 		$3.33M Buy
+14,000
New +$2.99M 0.02% 1393

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Cubist Systematic Strategies's ALNY Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2025: 1,352 shares worth $616K. The stake represents ﹤0.01% of the portfolio and ranks #2181 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in ALNY as recently as Q1 2024.

Cubist Systematic Strategies first reported a position in ALNY in Q2 2014 and has held it in 38 quarters since. The position peaked at $20.6M in Q3 2022. 822 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Cubist Systematic Strategies held 1,352 shares of Alnylam Pharmaceuticals worth $616K as of Q3 2025.
  • Alnylam Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2181 holding.
  • Cubist Systematic Strategies first reported a position in Alnylam Pharmaceuticals in Q2 2014 and has held it in 38 quarters since.
  • Cubist Systematic Strategies's Alnylam Pharmaceuticals position peaked at $20.6M in Q3 2022.
  • 822 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.